HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy...
Hence then, the article about akeso announces the publication of its phase iii clinical trial results for ivonescimab in head to head comparison with pembrolizumab in the lancet was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet )
Also on site :
- Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
- Reported tornado rips roofs off multiple homes in central Illinois
- MayimFlow wants to stop data center leaks before they happen